Use of non-formulary high-cost medicines in an Australian public hospital
暂无分享,去创建一个
[1] R. Moots,et al. Biosimilars: From Extrapolation into Off Label Use. , 2018, Current pharmaceutical design.
[2] G. Schumock,et al. National trends in prescription drug expenditures and projections for 2017. , 2017, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[3] J. Bosch,et al. Outcomes of off-label drug uses in hospitals: a multicentric prospective study , 2014, European Journal of Clinical Pharmacology.
[4] P. Pillans,et al. Experience with low‐dose rituximab in off‐label indications at two tertiary hospitals , 2013, Internal medicine journal.
[5] P. Jolliet,et al. Off-label prescriptions: how to identify them, frame them, announce them and monitor them in practice? , 2013, Therapie.
[6] J. Bosch,et al. Available evidence and outcome of off-label use of rituximab in clinical practice , 2013, European Journal of Clinical Pharmacology.
[7] Christine Y. Lu,et al. Access to high cost drugs in Australia , 2004, BMJ : British Medical Journal.
[8] G. Gallego,et al. Impact of High‐Cost Drugs for Individual Patient Use , 2004 .
[9] R. Day,et al. Drug and therapeutics committees — are they fulfilling their potential to improve the quality use of medicines? , 2003 .
[10] J. Green,et al. Evaluating a restrictive formulary system by assessing nonformulary-drug requests. , 1985, American journal of hospital pharmacy.
[11] T Fredriksson,et al. Severe psoriasis--oral therapy with a new retinoid. , 1978, Dermatologica.